PMID- 32568125
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 1875-8894 (Electronic)
IS  - 1874-5393 (Linking)
VI  - 13
IP  - 2
DP  - 2020
TI  - A pragmatic approach to Botulinum Toxin safety.
PG  - 195-199
LID - 10.3233/PRM-200716 [doi]
AB  - Botulinum Toxin (BoNT) is widely used to treat hypertonia in pediatric patients. 
      Although serious adverse events (AEs) occur infrequently, they can lead to 
      significant patient morbidity and mortality. This paper will discuss potential 
      safety risks that may affect outcomes, medical comorbidities, medication dosing, 
      targeting techniques, and muscle morphology. It is the responsibility of the 
      physician to discuss risks and benefits regarding the use of BoNT and mitigate 
      risks of AEs while maximizing the effectiveness of the medication.
FAU - Vova, Joshua A
AU  - Vova JA
FAU - Leung, Enoch
AU  - Leung E
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Pediatr Rehabil Med
JT  - Journal of pediatric rehabilitation medicine
JID - 101490944
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins)
SB  - IM
MH  - Botulinum Toxins/*adverse effects/therapeutic use
MH  - Cerebral Palsy/*drug therapy/rehabilitation
MH  - Child
MH  - Humans
MH  - Injections, Intramuscular
MH  - Muscle Spasticity/drug therapy/rehabilitation
MH  - Neuromuscular Agents/*adverse effects/therapeutic use
MH  - *Patient Safety
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Botulinum Toxin
OT  - black box warning
OT  - cerebral palsy
OT  - hypertonia
OT  - pediatric rehabilitation
OT  - safety
OT  - spasticity
EDAT- 2020/06/23 06:00
MHDA- 2021/06/17 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - PRM200716 [pii]
AID - 10.3233/PRM-200716 [doi]
PST - ppublish
SO  - J Pediatr Rehabil Med. 2020;13(2):195-199. doi: 10.3233/PRM-200716.